盐酸埃克替尼治疗晚期非小细胞肺癌疗效和安全性研究

辛涛1 ，辛向兵2 ，韩丰立3

（1.第四军医大学唐都医院呼吸科，陕西 西安，710038；2.第四军医大学唐都医院胸外科，陕西 西安，710038；3.陕西省第四人民医院神经内科，陕西 西安，710000）

浏览次数：265次 下载次数：490次

摘要：

目的 评估盐酸埃克替尼治疗携带表皮生长因子受体（EGFR）敏感基因突变的晚期非小细胞肺癌（NSCLC）患者的临床疗效和安全性。方法 将80例携带EGFR敏感基因突变的晚期NSCLC患者随机分为试验组和对照组，每组40例。试验组给予盐酸埃克替尼和盐酸厄洛替尼模拟片治疗，对照组给予盐酸厄洛替尼片盐酸埃克替尼模拟片治疗。比较两组患者的疗效、总生存期（OS）、无进展生存期（PFS）及不良反应发生情况。结果 治疗后，试验组的OR为37.5%，DCR为 65.0%，OS为13.9个月和PFS为9.1个月；而对照组的OR为22.5%，DCR为47.5%，OS 为10.2个月，PFS为7.4个月。两组比较，各疗效评价指标差异均有统计学意义（P<0.05）。两组不良反应比较，试验组患者恶心呕吐发生率显著低于对照组（P<0.05）。结论 盐酸埃克替尼治疗携带EGFR敏感基因突变晚期NSCLC患者的疗效和不良反应情况均优于盐酸厄洛替尼，具有重要的临床参考价值。

关键词：表皮生长因子受体；非小细胞肺癌；盐酸埃克替尼；安全性

中图分类号：R734.2文献标志码：A文章编号：2096-1413(2017)14-0001-03

Effect and safety of icotinib hydrochloride for treating advanced non-small cell lung cancer
XIN Tao 1, XIN Xiang-bing 2, HAN Feng-li 3
(1. Department of Pneumology, Tangdu Hospital of Fourth Military Medical University, Xi an 710038; 2. Department of Thoracic Surgery, Tangdu Hospital of Fourth Military Medical University, Xi an 710038; 3. Department of Neurology, the Fourth People s Hospital of Shaanxi,

Xi an 710000, China)

ABSTRACT: Objective To evaluate the effect and safety of icotinib hydrochloride (IH) for treating advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) sensitive gene mutations. Methods Eight advanced NSCLC patients with EGFR sensitive gene mutations were randomly divided into experimental group and control group, with 40 patients in each group. The experimental group received IH plus erlotinib hydrochloride (EH) mimetic tablet, while the control group received EH tablet and IH mimetic tablet. The effect, overall survival (OS), progression-free survival (PFS) and adverse events were compared between the two groups. Results After treatment, the OR was 37.5%, DCR was 65.0%, OS was 13.9 months and PFS was 9.1 months in the experimental group. However, the OR was 22.5%, DCR was 47.5%, OS was 10.2 months and PFS was 7.4 months in the control group. There were significant differences between the two groups in the evaluation indexes (P<0.05). The incidence of nausea and vomiting in the experimental group were significantly lower than those in the control group (P<0.05). Conclusion The effect and safety of IH is superior to EH for treating advanced NSCLC patients with EGFR sensitive gene mutations, which has important clinical reference value.

KEYWORDS: epidermal growth factor receptor (GEFR); non-small cell lung cancer (NSCLC); icotinib hydrochloride; safety

参考文献：
[1] SIEGEL R.Cancer statistics,2012[J].CA Cancer J Clin,2012,60(1):10-29.

[2] 张凌云,易铁男.盐酸埃克替尼治疗晚期肺腺癌155例[J].实用临床医药杂志,2015,19(21):147-149.
[3] 尹月,邱新野.盐酸埃克替尼治疗107例晚期非小细胞肺癌临床观察[J].中国医刊,2016,51(12):57-59.
[4] 旷琛,陈敏.埃克替尼治疗晚期非小细胞肺癌的系统评价[J].中国药房,2016,27(9):1219-1222.
[5] 赫杰,赵平,陈万青.2012中国肿瘤登记年报[M].北京:军事医学科学出版社,2012:29.
[6] 孟苗.埃克替尼治疗晚期非小细胞肺癌的疗效观察[J].中国实用医药,2016,11(20):166-167.
[7] 张琳琳.盐酸埃克替尼治疗非小细胞肺癌合并EGFR突变临床疗效[J].临床军医杂志,2016,44(8):841-843.
[8] 朱礼阳,许春伟,于忠和.埃克替尼治疗37例晚期非小细胞肺癌疗效分析[J].临床与病理杂志,2016,36(9):1340-1344.